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IntroduCtIon
Clinical imaging modalities, such as computed tomography (CT), 
positron emission tomography, or magnetic resonance (MR) imag-
ing, are critical cornerstones in diagnosis and management of 
modern oncology.1-3 The maturity of these modalities and proto-
cols of implementation have reached such a degree of sophistica-
tion, that properly obtained studies can supplant the need for a 
tissue biopsy in some diseases, such as the Liver Imaging 
Reporting And Data System for hepatocellular carcinoma (HCC).4,5 
Even though the diagnostic protocol for liver cancer is increasingly 
refined, the prognosis of liver cancers remains unsatisfactory, 
which is the second most common cause of death from cancer 
worldwide.6 Moreover, it is highlighted that variable biologic be-
havior of liver cancers affects patients’ survival, and the tumoral 
heterogeneity can be also an important clue in determining the 
likelihood of a clinical response to treatment.7,8 Thus, the trend of 
diagnosis and treatment for liver cancers is changing to be deter-
mined by significant biological and genomic characteristics of the 
tumors, and imaging can be also a method to find these 
characteristics.9-12 
In contrast to serologic markers, the majority of imaging find-
ings reported from radiologic studies involves qualitative or de-
scriptive features. Moreover, the interobserver variability when ra-
diologists define the imaging findings remains an unresolved 
issue.13 Recently, new research methods to explore imaging bio-
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markers through objective and quantitative analyses of medical 
images including radiologic studies, have been developed into an 
academic discipline that studies the association of the imaging 
parameters with patient information, and several studies have 
been published in a variety of carcinomas.14,15   
However, this state-of-the-art method is still in its infancy, es-
pecially in the liver cancer research; various attempts have been 
made and presented in the annual meeting of Radiological Soci-
ety of North America (RSNA) in 2017. This review article focuses 
on the preliminary clinical application of radiomics, and 
radiogenomics (or imaging genomics) for primary liver cancers, 
such as HCC and intrahepatic cholangiocarcinoma (ICC). 
WhAt Are rAdIomICs, rAdIogenomICs, 
And ImAgIng genomICs?
Radiomics is a method of research that extracts quantitative ra-
diologic data from medical images (radiomic data) and explores 
the correlation with clinical outcomes.14 Radiogenomics (or imag-
ing genomics) also aims to identify relationships between seman-
tic as well as quantitative image data with genome and molecular 
measurements in order to construct association maps that can in 
turn be correlated with outcome or other clinical measures.15-17 A 
requisite for both radiomics and radiogenomics is the identifica-
tion of an objective manner to transform the imaging features into 
digital data, which is also important for insuring reproducibility. 
The general radiomics workflow involves, 1) acquisition of images, 
2) identification of region of interest (by human or machine learn-
ing), 3) segmentation of region of interest (by automatic, semi-
automatic, or manual drawing), 4) extraction of imaging features, 
and 5) mining the data to develop model to predict clinical out-
comes (Fig. 1).
For radiomics and radiogenomics, it is possible to analyze the 
medical images archived in the imaging server of the hospital ret-
rospectively, and the more imaging database has sufficient data, 
the more accurate predictive radiomic model can be made. How-
ever, the variability of imaging quality and technical parameters 
for image acquisition may influence the image features and results 
of predictive models. 
Figure 1. The process of radiomics and radiogenomics. In comparison to the current conventional imaging study interpretation, radiomic and radi-
ogenomic approaches require multiple processing steps (automated as well as semi-automated steps including registration, segmentation, region of 
interest selection, measurement, etc.). As the fields develop and methodologies become more standardized these steps may also become “implicit” in 
the image processing component, similar to the processing of raw computed tomography (CT) or magnetic resonance (MR) data before transmission 
to clinical PACS. Selected icons adapted and reprinted from Lubner et al.19, with permission from Radiological Society of North America (RSNA). PACS, 
picture archiving and communication system.
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rAdIologICAl ImAgIng trAIts: quAntI-
tAtIve versus quAlItAtIve methods
The gold standard of radiologic image interpretation continues 
to be expert (radiologist) based reads, in spite of digital acquisi-
tion (or conversion) of clinical imaging data. In order to convert 
these images into parametric data objectively, it should be helped 
by specific analytic method, feature analysis (FA). FA is a 
quantitative method of objectively assessing tumor heterogeneity 
or parenchymal change in specific disease by exploring the distri-
bution and connection of pixel or voxel gray levels in the CT im-
age.18 There are several parts, such as the gray-level frequency 
distribution from the pixel intensity histogram in a given region of 
interest,  a co-occurrence matrix which considers the location of 
pixels and spatial relationship between pixels, and  neighborhood 
gray-tone difference matrices which examine location and rela-
tionship between three or more pixels. In addition, model-based 
and transform-based methods are used for FA (Fig. 2).19
Performance of quantitative analyses has multiple prerequisites. 
First of all, reasonable segmentation of the tumor should precede 
the FA. Segmentation is the most critical component because the 
subsequent feature data are generated from the segmented vol-
umes, but it is still challenging due to indistinct border of the tu-
mors.16 At this step, it is vulnerable to be disturbed by reviewer’s 
subjectivity; therefore, automatic or semi-automatic segmentation 
methods are preferred to manual methods,20 especially for liver 
cancers of which tumor-parenchyma differentiation may be not 
clear compared with lung and breast cancers. Second, denoising 
and gray-level standardization can affect the analytic result, espe-
cially second- and high-order statistics, thus these should be per-
formed properly in the pre-processing steps to aid in reproducibil-
ity of the analysis.
One advantage of descriptive or qualitative features is that they 
frequently describe physiological or biological processes. For 
example, there is a largely accepted explanation for arterial phase 
enhancement of HCC masses in contrast-enhanced CT and MR im-
ages. The development of HCC frequently involves neovascularization 
of unpaired arteries that do not have associated portal tracts,21,22 
thus increasing arterial flow through the unpaired artery as 
compensation for decrease of portal flow in the tumor. Conse-
Figure 2. An example of acquiring texture parameters through feature analysis. Following selection of an appropriate the region of interest (white 
arrow) of an image, (A) a histogram of gray-level intensity and distribution can be drawn. From the histogram, several statistical measures including 
mean, mean of the positive pixel, standard deviation can be calculated (A). The distributions of the measurements can further be characterized in 
terms of their (B) skewness, and (C) kurtosis. Modified and reprinted from Lubner et al.19, with permission from Radiological Society of North America 
(RSNA).
A
B
C
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quently, contrast media goes into the tumor early on the arterial 
phase and goes out of the tumor through veins on following 
phases, called as wash-out.23 Nowadays, these findings have 
been considered as hallmarks for imaging diagnosis of HCC.4,5 
While it is often reassuring when such features have a demon-
strated (patho-)physiological description, a challenges is the diffi-
culty with inter-observer , and even intra-observer, variability.5
BIologIC And genomIC ChArACterIstICs 
oF lIver CAnCers
HCC is the most common primary cancer in the liver. It is known 
to be a quiet killer with minimal symptoms at the early stages of 
disease, frequently occurring in the context of hepatitis infections 
and cirrhosis leading to end-stage liver disease, in addition to 
largely unknown tumor genetic factors. Current staging systems, 
such as Barcelona Clinic Liver Cancer staging system, do not take 
into account the histologic and molecular characteristics of the 
tumor.9
According to recent studies, HCCs exhibit intra-individual and 
inter-individual genetic heterogeneity. Predicting biologic behavior 
of HCC is essential for an appropriate treatment, and investigators 
have found that patient prognosis is not only related to size of tu-
mor and multiplicity, but also the pathologic features such as his-
tologic grade of tumor, microvessel density, microscopic vascular 
invasion (MVI), and epithelial-mesenchymal transition (EMT).24-26 
Histologic grade of HCC accounts for a combination of structur-
al and cellular features and is a significant predictor. According to 
a meta-analysis of 114 related articles, poor tumor differentiation 
correlated with worse prognosis.27 However, there was a limita-
tion of divergences and inaccuracies led by a non-standardized 
grade distribution. Microvessel density, which allows semi-quanti-
tative assessment of tumor neovascularization (CD31, CD34, and 
von Willebrand Factor), is known as a significant prognostic fac-
tor. Vascular endothelial growth factors (VEGFs) and hypoxia-in-
ducible factors (HIFs) are also negative prognostic markers related 
to reduce overall survival and recurrence-free survival after tumor 
resection.28 
MVI is another well-known factor suggesting poor prognosis. In 
the large-scale retrospective study which observed transplanted 
patients’ survival, the authors revealed a doubling in the hazard 
of death was associated with the presence of MVI.29 EMT is an-
other pathologic feature to predict prognosis and it increases in-
vasiveness of tumor and metastatic potential.30,31 
In terms of genomic markers, in order to accurately predict ther-
apeutic response of targeted therapy based on tumor molecular 
profiles, there have been efforts to identify critical molecular sub-
classes with different prognostic consequence, and associated ge-
netic or epigenetic drivers of specific subclasses. 
Some investigators have proposed molecular classifications of 
HCC using mRNA-based gene expression based on biological pro-
cesses (e.g. proliferation) and protein markers (e.g. EpCAM and 
cytokeratin 19 [CK19]).32 Villanueva et al. focused on both the tu-
mor and nontumoral-adjacent cirrhotic tissue in order to identify a 
genomic signature predictive of patients’ outcome, and they sug-
gested a model for prediction of recurrent HCC combining clinical, 
pathology, and genomic data.33
ICC is another aggressive primary liver cancer and new studies 
are identifying pathologic biomarkers that reflect the biological 
behavior of the tumor. Overexpression of epidermal growth factor 
receptor (EGFR) was an independent prognostic parameter along 
with tumor stage.34 EGFR, VEGF, and human epidermal growth 
factor receptor 2 were also significantly related to macroscopic 
type, nodal metastasis, lymphatic vessel invasion, perineural inva-
sion and tumor stage.35 
KRAS mutation was found in up to 40% of cholangiocarcinoma, 
but predominantly in perihilar and distal tumors.36 Because direct 
therapeutic inhibition of KRAS is difficult, targeted therapy aims 
at modulation of downstream signaling along the KRAS pathway. 
Recently, Graham et al. identified FGFR2 translocation in ICC, and 
it could be benefited from FGFR-targeted therapy.37  
Like HCC, microvessel density and EMT may play a role as bio-
markers to indicate prognosis of ICC. Microvessel density and 
lymphatic microvessel density were frequently displayed in ad-
vanced ICC, and the patients of which microvessel density was 
high had an inferior curative resection rate and frequently devel-
oped recurrence.38 In addition, the high expression of N-cadherin 
and S100A4, the pathologic evidences of EMT, were indepen-
dently significant prognostic factors in ICC.39 
Where do We stAnd on the rAdIomICs 
And rAdIogenomICs For prImAry lIver 
CAnCer?
There are limited quantitative analyses of imaging studies in the 
hepatic tumors to date although some researchers have focused 
on texture analysis. Most of the studies have focused on the rela-
tionship between imaging traits and clinical characteristics includ-
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ing survival, recurrence, and treatment response after chemother-
apy. In contrast, some studies dealt with the relationship between 
the genomic signatures and imaging findings (without texture 
analysis); therefore, radiogenomic analysis for liver cancer is very 
rare so far (Table 1).40,41 
The majority of the studies have centered on HCC, and been 
based on CT texture with only some studies which investigated 
the role of MRI.16 At the 2017 RSNA Conference, there were sever-
al presentations about radiomics of HCC using MRI, especially ga-
doxetic acid-enhanced MRI.
HCC
The first radiogenomic study of HCC was performed in 200710 
and involved measurement of quantitative as well as semantic im-
aging features. They found that combination of 28 imaging traits 
could reconstruct the variation of all 116 gene models, about 
80% of global gene expression profiles, revealing cell prolifera-
tion, liver synthetic function, and patient prognosis. Among the 
imaging traits, the presence of internal arteries and the absence 
of a hypodense halo were associated with MVI genomic signa-
tures that were comprised of genes involved in cell proliferation 
(CDK, CDC20, MCM5) and matrix invasion (ADAMTS1, MMP14, 
SPARCL1). On a subsequent study, the CT-based imaging traits 
were evaluated to predict the presence of MVI on pathologic 
specimen, and additional imaging trait, the absence of tumor-liver 
difference, was considered the third imaging trait for “radioge-
nomic venous invasion” imaging signature as well as the estab-
lished two imaging traits. This signature was not only accurate to 
diagnose MVI but associated with lower overall survival.11 
Villanueva et al.33 investigated the genomic features of HCC and 
peritumoral tissue that were associated with patients’ outcome, 
who tried to explore the relationship between imaging trait and 
genomic signatures.42 Patients who underwent pre-operative CT 
or MR imaging before surgery as well as transcriptome profiling 
were assessed 11 qualitative and four quantitative (size, enhance-
ment ratios, wash-out ratio, tumor-to-liver contrast ratio) imaging 
traits. Several imaging traits including infiltrative pattern and 
macrovascular invasion were associated with gene signatures of 
aggressive HCC phenotype such as proliferative signatures and 
CK19 signature. 
More recently a radiomics signature derived from texture analy-
sis was proposed to be a surrogate for MVI in HCC, prediction of 
patients’ survival, and early recurrence.43-45 This study involved 28 
HCC patients who underwent resection and evaluated some im- ta
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aging textures and “delta features” defined as the absolute dif-
ference or the ratio calculated from all pairs of imaging phases 
(e.g. precontrast minus arterial phase Hounsfield units).43 Among 
464 features, single and delta features between arterial and por-
tal-venous phases were robust to detect MVI. Another research 
group published that contrast-enhanced MR-based texture analy-
sis could differentiate pathologic grade.46 Forty-six patients who 
performed contrast-enhanced MRI before tumor resection were 
enrolled and arterial phase images were used for analysis. Histo-
logical low-grade HCCs had increased mean intensity and de-
creased gray-level run-length non-uniformity in four directions. 
This suggest that internal heterogeneity could be an imaging fea-
ture reflecting high-grade HCC, which has poor clinical prognosis. 
Recently, a study group tried to explore the CT-based radiomics 
data which related to key genomic information such as doxorubi-
cin-resistant genes (TP53, TOP2A, CTNNB1, CDKN2A and AKT1), 
and they identified radiomics signatures to successfully discrimi-
nate these chemo-resistant genes.41 
The majority of studies to date have focused on CT imaging fea-
tures, however, now several MR imaging based studies are 
emerging and features associated with MVI have been found, 
such as decreased apparent diffusion coefficient (ADC) on diffu-
sion weighted imaging,47 peritumoral enhancement, non-smooth 
tumor margin,48 and peritumoral hypointensity on hepatobiliary 
phase imaging following gadoxetic acid injection.49 There are 
some MR imaging sequences, such as diffusion, that can provide 
information that is not measurable by CT,50 thus radiomic MR fea-
tures are of great interest. However, MR imaging is more vulnera-
ble to imaging artifacts such as motion and magnetic susceptibili-
ty, thus reproducibility between different scanners and even the 
same scanner is a non-trivial challenge. Additionally the signal in-
tensity of MR imaging is not easy to be digitalized compared to 
CT imaging (Hounsfield units), which is easy to be modulated and 
standardized for radiomic analyses. 
Last year at the RSNA Conference (2017), three results on MR-
based radiomics analysis for HCC were presented. Hui et al. 
sought to predict early recurrence after resection using MR imag-
ing.51 The study involved 57 patients that were separated into co-
horts with early recurrence or not, using texture analysis of con-
trast and entropy in the arterial phase with 79% accuracy. Chen 
et al. showed texture analysis on the perfusion MR imaging could 
be associated with Edmudson-Steiner grades, and skewness of 
area under curve map was revealed as a potential marker to pre-
dict histologic grades.52 Hectors et al. analyzed MR imaging tex-
ture on multiparametric MRI including blood oxygenation level 
dependent imaging and dynamic contrast enhanced-MRI, and in-
vestigated the correlation with HIF-1α and gene expression of 
Wnt target GLUL, pharmacological target FGFR4, stemness mark-
ers EpCAM and KRT19 and immune checkpoint PDCD1.53 
Intrahepatic cholangiocarcinoma
To date there has only been one radiogenomics ICC study. 25 
enrolled patients with histologically proven ICC were evaluated 
according to CT-based textures and immunochemistry findings 
suggesting tissue hypoxia, such as EGFR, VEGF, CD24, TP53, 
MDM2, MRP-1, HIF-1α, CA-IX, and GLUT1.12 Following multiple 
variable regression, three imaging phenotypes, entropy, correla-
tion, and homogeneity, were significantly associated with EGFR 
expression and correlation phenotype was associated with VEGF 
expression level although visual (qualitative) features were not as-
sociated with all of hypoxia markers. Another retrospective study 
tried to reveal which CT imaging phenotypes were associated 
with patient’s survival and tumor genetics. CT imaging features 
were semantic and not quantitative; for example, central fibrosis, 
well-defined border, homogeneity of enhancement, central necro-
sis, liver surface retraction, vascular encasement, tumor thrombus, 
satellite lesions, intrahepatic metastasis and lymphadenopathy.54 
They found that necrosis, satellite nodule, and vascular encase-
ment might be associated with a higher risk of death. However, 
they could not find the relationship between imaging features and 
genetic mutation such as IDH1 and KRAS gene. 
Several published studies investigated imaging findings as relat-
ed to patient outcome after resection. Asayama et al. evaluated 
delayed phase CT exams in a cohort of 32 patients and observed 
that the degree of enhancement correlated with the amount of fi-
brous stroma and the frequency of perineural invasion.55 The sur-
vival of patients was also associated with the degree of enhance-
ment.55 Lee et al. explored that diffusion-weighted image could 
predict patients’ survival after resection.56 Multivariate regression 
test revealed that degree of diffusion restriction was associated 
with patients’ survival, as well as histologic differentiation and in-
trahepatic metastasis on pathology. 
A quantitative MR imaging study by Pandey et al.57, explored 
imaging feature changes in 72 patients with unresectable ICC and 
underwent two MRI examinations before and after chemotherapy. 
Paradoxically, ADC values on the baseline study were lower and 
percent of viable tumor volume was higher in the group with lon-
ger survival (>10 months); it was hypothesized that radiologically 
viable tumor was more responsive to the chemotherapy. 
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Future perspeCtIves oF rAdIomICs: 
strengths And WeAknesses
The preceding studies suggest that radiomic and radiogenomic 
approaches can be useful in gaining deeper insights into tumor 
genetics, biology, and clinical outcome. MR in particular likely has 
many new applications with the development of functional pulse 
sequences in addition the anatomical information, although stan-
dardization of protocols and image scans will continue to be a 
challenge for quantitative imaging analysis. It is conceivable that 
in the future, we will be able to use radiomics-based decision 
making tool to diagnose incidental hepatic lesion or to decide 
which treatment is best to the disease. Artificial intelligence and 
deep learning will also likely have roles to play in the future of ra-
diomics and radiogenomics, particularly with regards to registra-
tion and segmentation of imaging studies.
Quantitative imaging approaches, including imaging texture 
analysis, reflect a departure from the historical, largely subjective 
approach for medical image interpretatin. The merit of this new 
method is that it is able to get digital information (data) from 
medical imaging and when performed under appropriate proto-
cols, is more robust and reproducible than strictly human based 
interpretations, i.e., radiologist. A potential advantage is that in-
formation that may be “hidden” can be discerned with quantita-
tive approaches. On the same token, there is a knowledge base 
that the radiologist has that radiomic based approaches have not 
yet achieved. Although there are too many variables to reliably 
predictive the future, it is likely that at a minimum these automat-
ed (or semi-automated) approaches will support the diagnostic 
and decision-making processes in medical imaging.
Nevertheless, there are remaining issues for clinical use. First, 
reproducibility is a very important issue.14 This is related to many 
factors, such as imaging acquisition protocol, method of segmen-
tation, method for extracting imaging features, and acquisition of 
clinical and genomic data. With respect to tumor markers, the 
standard reporting recommendations (REporting recommenda-
tions for tumour MARKer prognostic studies, REMARK) has been 
established for over 10 years.58 In a similar vein, standardization 
of analysis methodologies in radiomics and radiogenomics will be 
necessary if these methods are to gain broad adoption in the im-
aging community. Second, estimating appropriate sample size is 
another important issue. While larger data sets and “big data” 
provide great promise to identify new predictors of survival and 
outcome, associations do not imply causality.17 Third, although 
many radiomic studies have been implemented retrospectively, 
ideally a prospective study design is preferable. Additionally multi-
site hospitals may help increase the study size number and statis-
tical power but at the cost of increased variability in standardiza-
tion of protocols and data processing.17
ConClusIon
While oncologic radiomics and radiogenomics are in early stag-
es of development there is much to be gained from continued in-
vestigations in order to maximize the utility of non-invasive diag-
nostic tests and potential molecular and genomic correlates of 
imaging features. Towards this end they may also advance the 
objectives of precision medicine as well as more cost effective 
healthcare.
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